SecBot SecBot
SECBOTREPLAY Home › Report › RVMD

RVMD · Revolution Medicines reported its 2025 financial results, highlighting…

Revolution Medicines, Inc. · 8-K filed Feb 25, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Feb 25, 2026 at 16:05 ET

Revolution Medicines reported its 2025 financial results, highlighting a $1.1 billion net loss on $987.3 million in R&D expenses as it advances a broad late-stage oncology pipeline. The company maintains a strong $2.0 billion cash position and provided 2026 operating expense guidance of $1.6-$1.7 billion, reflecting continued heavy investment in clinical development.

  • Cash, cash equivalents and marketable securities were $2.0 billion as of December 31, 2025
  • R&D expenses were $987.3 million for 2025, up from $595.2 million in 2024
  • Net loss was $1.1 billion for 2025, compared to $600.1 million in 2024
  • 2026 GAAP operating expenses are guided to be between $1.6 and $1.7 billion

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access